Vnitr Lek 2006, 52(7-8):749-755

Present possibilities of diagnostics and therapy of osteoporosis

P. Horák*, T. Pika
III. interní klinika Lékařské fakulty UP a FN, Olomouc, přednosta prof. MUDr. Vlastimil Ščudla, CSc.

The occurence of osteoporosis is not so poor in industrial countries, together with advance of socioeconomical level and spreading of human life's lenght, increases the prevalence of osteoporosis, affect about 5-6 % of Europe population and also raises the number of the most consequential results - fractures, complications, dramatically deteriorating health state and limiting social self-realization of the pacients. Osteoporosis belongs to metabolic bone diseases with highly clarified mechanisms of bone tissue decrease and comprehensive diagnostic platform, based on combination of imaging and laboratory methods, enabling early disease detection, before occurence of fracture complications. In sequence of disorder etiology, the adequate therapy is known with continualy increasing effectivity and aplication simplicity for pacient, increasing his compliance. Increasing public knowledge and prevention put back not only occurance of complications, but also onset of the disease. Neverthless, the osteoporosis is still hidden danger with serious economic and social impact.

Keywords: osteoporosis; diagnostic of osteoporosis; osteoporosis therapy

Received: March 1, 2006; Published: July 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horák P, Pika T. Present possibilities of diagnostics and therapy of osteoporosis. Vnitr Lek. 2006;52(7-8):749-755.
Download citation

References

  1. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843: 1-129. Go to PubMed...
  2. Broulík P. Osteoporóza. Praha: Maxdorf Jessenius 1999.
  3. Blahoš J. Osteoporóza, Praha: Galén 1996.
  4. Štěpán J. Syndrom osteoporózy. Praha: Avicenum 1990.
  5. Favus MF (ed). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 3rd ed. Philadelphia-New York: Lippincott 1996.
  6. Cooper C, Melton LJ 3rd. Epidemiology of osteoporosis. Trends Endocrinol Metab 1992; 3(6): 224-229. Go to original source... Go to PubMed...
  7. Geusens P (ed). Osteoporosis in Clinical Practice. London: Springer Verlag 1998. Go to original source...
  8. Kocián J. Osteoporóza u mužů. Praha: Triton 2002.
  9. Cooper C, O'Neill T, Silman A. The epidemiology of vertebral fracture. Bone 1993; 14: S89-S97. Go to original source... Go to PubMed...
  10. Cauley JA, Thompson DE, Ensrud KC et al. Risk of mortality following clinical fractures. Osteoporosis Int 2000; 11: 556-561. Go to original source... Go to PubMed...
  11. Rizzoli R. Atlas of Postmenopausal Osteoporosis. 2nd ed. London: Current Medicine Group Ltd 2005.
  12. Dequeker J, Pearson J, Reeve J et al. Dual-energy X ray absorptiometry - cross-calibration and normative reference ranges for the spine; results of a European Community Concerted Action Bone 1995; 17: 247-254. Go to original source... Go to PubMed...
  13. Pearson J, Dequeker J, Reeve J et al. Dual-energy X ray absorptiometry of the proximal femur; normal European values standardised with the European Spine Phantom. J Bone Miner Res 1995; 10: 315-324. Go to original source... Go to PubMed...
  14. Kans JA, Borgstrom F, De Late C et al. Assessment of fracture risk. Osteoporos Int 2005; 16: 737-742. Go to original source... Go to PubMed...
  15. Faulkner KG, Cummings SR et al. Simple measurement of femoral geometry predicts hip fracture: the study of osteoporotic fractures. J. Bone Miner Res 1993; 8: 1211-1217. Go to original source... Go to PubMed...
  16. Bergot C, Bousson V et al. Hip fracture risk and proximal femur geometry from DXA scans. Osteoporosis Int 2002; 13: 542-550. Go to original source... Go to PubMed...
  17. Pulkkinen P, Partanen J et al. Combination of bone mineral density and upper femur geometry improves the prediction of hip fracture. Osteoporosis Int 2002; 15: 274-280. Go to original source... Go to PubMed...
  18. Genant HK, Guglielmi G, Jergas M (eds). Bone Densitometry and Osteoporosis. Berlin-Heidelberg: Springer-Verlag 1998. Go to original source...
  19. Kroger H, Heikkinen J, Laitinen K et al. Dual Energy X-ray Absorptiometry in normal women: a cross-sectional study of 717 Finnish volunteers. Osteoporos Int 1992; 2: 135-140. Go to original source... Go to PubMed...
  20. Johnell O, Oden A, De Laet C et al. Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int 2002; 13: 523-526. Go to original source... Go to PubMed...
  21. Stepan JJ. Clinical utility of bone markers in the evaluation and follow-up of osteoporotic patients: Why are the markers poorly accepted by clinicians? J Endocrinol Invest 2003; 26: 458-463. Go to original source... Go to PubMed...
  22. Eastell R, Baumann M, Hoyle NR et al. Bone Markers. London: Martin Dunitz Ltd 2001.
  23. American Association of Clinical Endocrinologists. Medical guidelines for clinical practive for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003; 9: 544-564. Go to original source...
  24. Richy F, Ethgen O, Bruyere O et al. Efficacy of alphacalcidiol and calcitriol in primary and corticoid-induced osteoporosis: a metaanalysis of their effects on bone mineral density and fracture rate. Osteoporosis Int 2004; 15: 301-310. Go to original source... Go to PubMed...
  25. Cauley JA, Robbins J, Chen Z et al. Effect of estrogen plus progestin on risk of fracutre and bone mineral density. The Women's Health Initiavive Randomised Trial. JAMA 2003; 290: 1729-1738. Go to original source... Go to PubMed...
  26. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifen: results form a 3-year randomised clinical trial. JAMA 1999; 292: 637-645. Go to original source... Go to PubMed...
  27. Fleisch H Bisphosphonates in Bone Diseases. Academic Press, San Diego 2000Mc Clung M.R. Bisphsophonates. Endcrinol metab Vlin North Am 2003; 32: 253-271. Go to original source... Go to PubMed...
  28. Reginster JY, Minne HW, Sorensesn OH et al. Randomised trial of the efects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11: 83-91. Go to original source... Go to PubMed...
  29. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effects of alendronate on risk of fracture in women with existinn vertebral fractures. Lancet 1996; 348: 1535-1541. Go to original source... Go to PubMed...
  30. Chesnut III CH, Skag A, Christiansesn C et al. Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracute risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-1249. Go to original source... Go to PubMed...
  31. Chesnut CH, Silverman S, Adrianoi K et al. A randomised trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis. The Prevent Recurrence of Osteoporotic Fracture Study. Am J Med 2000; 109: 267-276. Go to original source... Go to PubMed...
  32. Payer J jr, Killinger Z, Ondrejak P. Lososí kalcitonin v liečbe osteoporózy. Vnitř Lék 1999; 45: 476-479. Go to PubMed...
  33. Neer RM, Arnaud CD, Zanchetta JR et al. Effects of parathyroid hormone (1-34) on fractures and bone mineral density on postmenopausla women with osteoporosis. N Engl J Med 2001; 344: 1334-1441. Go to original source... Go to PubMed...
  34. Meunier PJ, Roux C, Seeman E et al. The effect of Strontium Ranelate on the risk of vertebral fracture in Women with postmenopausal osteoporosis. N Engl J Med 2004; 350(5): 459-468. Go to original source... Go to PubMed...
  35. Reginster JY, Balogh A, Badurski J et al. Strontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women without prevalent fracture. Osteopor Int 2003; 14: S7-S8.
  36. Reginster JY, Meunier PJ, Roux C, Compston J, Ortolani S. Strontium ranelate: An antiosteoporotic treatment demonstrated vertebral and nonvertebral anti fracture efficiacy over 5 years in post menopausal osteoporotic women. OC31. 6th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, 15.-18. 3. 2006, Vídeň (Rakousko).




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.